Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis

被引:33
作者
Kirwan, John R. [1 ]
Clarke, Lynsey [1 ]
Hunt, Linda P. [2 ]
Perry, Mark G. [3 ]
Straub, Rainer H. [4 ]
Jessop, David S. [5 ]
机构
[1] Univ Bristol, Bristol Royal Infirm, Acad Rheumatol Unit, Bristol BS2 8HW, Avon, England
[2] Univ Bristol, Dept Clin Sci S Brisol, Bristol BS2 8HW, Avon, England
[3] Derriford Hosp, Plymouth Hosp NHS Trust, Plymouth PL6 8DH, Devon, England
[4] Univ Hosp, Dept Internal Med 1, Lab Neuroendocrinoimmunol, Regensburg, Germany
[5] Univ Bristol, Henry Wellcome Labs Integrated Neurosci & Endocri, Bristol BS2 8HW, Avon, England
来源
NEUROENDOCRINE IMMUNOLOGY IN RHEUMATIC DISEASES: TRANSLATION FROM BASICS TO CLINICS | 2010年 / 1193卷
关键词
IL-6; cortisol; arthritis; PITUITARY-ADRENAL AXIS; CORTISOL PRODUCTION; DISEASE-ACTIVITY; DOUBLE-BLIND; INTERLEUKIN-6; IMMUNE; DEFECT; TRIAL;
D O I
10.1111/j.1749-6632.2009.05289.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The morning stiffness and pain of rheumatoid arthritis (RA) is accompanied by a rise in serum interleukin-6 (IL-6) from 2 am to 7 am. Using a formulation that releases prednisone at 2 am (after ingestion at 10 pm), we studied the circadian dynamics of serum IL-6, other cytokines, and cortisol in 9 patients before and after 2 weeks, therapy. Significant improvements occurred in morning stiffness, pain, disease activity, and the acute-phase response. Only IL-6 showed measurable cytokine circadian variation, its high pretreatment peak was abolished, and changes in IL-6 correlated with the changes in morning stiffness. Following treatment, afternoon and evening serum cortisol was reduced, but in the early morning cortisol peak concentration increased. Thus the severity of morning symptoms is related to nocturnal serum IL-6 concentration. The specific timing of the medication, linked to the interaction between IL-6 and the hypothalamic-pituitary-adrenal (HPA) axis, may correct a postulated deficiency in HPA control in RA.
引用
收藏
页码:127 / 133
页数:7
相关论文
共 48 条
  • [1] Circadian rhythms and rheumatoid arthritis
    Cutolo, Maurizio
    JOINT BONE SPINE, 2019, 86 (03) : 327 - 333
  • [2] Circadian Use of Glucocorticoids in Rheumatoid Arthritis
    Cutolo, Maurizio
    Sulli, Alberto
    Pincus, Theodore
    NEUROIMMUNOMODULATION, 2015, 22 (1-2) : 33 - 39
  • [3] Nocturnal hormones and clinical rhythms in rheumatoid arthritis
    Cutolo, M
    Otsa, K
    Aakre, O
    Sulli, A
    AUTOIMMUNE DISEASES AND TREATMENT: ORGAN-SPECIFIC AND SYSTEMIC DISORDERS, 2005, 1051 : 372 - 381
  • [4] Glucocorticoids: action and new therapeutic insights in rheumatoid arthritis
    Kirwan, John
    Power, Lynsey
    CURRENT OPINION IN RHEUMATOLOGY, 2007, 19 (03) : 233 - 237
  • [5] The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis
    Cutolo, Maurizio
    Spies, Cornelia M.
    Buttgereit, Frank
    Paolino, Sabrina
    Pizzorni, Carmen
    ARTHRITIS RESEARCH & THERAPY, 2014, 16
  • [6] Glucocorticoids in rheumatoid arthritis: Balancing benefits and harm by leveraging the therapeutic window of opportunity
    Doumen, Michael
    Pazmino, Sofia
    Bertrand, Delphine
    Westhovens, Rene
    Verschueren, Patrick
    JOINT BONE SPINE, 2023, 90 (03)
  • [7] Rediscovering the therapeutic use of glucocorticoids in rheumatoid arthritis
    van der Goes, Marlies C.
    Jacobs, Johannes W. G.
    Bijlsma, Johannes W. J.
    CURRENT OPINION IN RHEUMATOLOGY, 2016, 28 (03) : 289 - 296
  • [8] Circadian rhythms of cellular immunity in rheumatoid arthritis: a hypothesis-generating study
    Spies, C. M.
    Hoff, P.
    Mazuch, J.
    Gaber, T.
    Maier, B.
    Strehl, C.
    Hahne, M.
    Jakstadt, M.
    Huscher, D.
    Burmester, G-R.
    Detert, J.
    Kramer, A.
    Buttgereit, F.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (01) : 34 - 43
  • [9] Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy
    Berardicurti, Onorina
    Ruscitti, Piero
    Pavlych, Viktoriya
    Conforti, Alessandro
    Giacomelli, Roberto
    Cipriani, Paola
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (06) : 593 - 604
  • [10] Current and novel therapeutic targets in the treatment of rheumatoid arthritis
    George, Genu
    Shyni, G. L.
    Raghu, K. G.
    INFLAMMOPHARMACOLOGY, 2020, 28 (06) : 1457 - 1476